Skip to content
    Clinical Trials

    Hypofractionated vs Conventional Breast Radiotherapy and Lymphocyte Recovery

    Song et alTherapeutic advances in medical oncology

    Hypofractionated vs Conventional Breast Radiotherapy and Lymphocyte Recovery
    In a secondary analysis of the prospective, multicenter, randomized phase III CHN-HYPOBREAST trial, investigators evaluated the longitudinal dynamics and recovery of peripheral lymphocyte counts (PLCs) in 203 patients with breast cancer treated with radiotherapy without chemotherapy following breast-conserving surgery. Patients were allocated to either hypofractionated radiotherapy (HFRT, n = 96) or conventional fractionated radiotherapy (CFRT, n = 107). PLCs were measured at baseline prior to any cancer therapy, pre-radiotherapy (after surgery but before radiotherapy), weekly during radiotherapy, and periodically for up to 5 years post-treatment, with longitudinal trends evaluated using generalized linear mixed models.
    Pre-radiotherapy lymphocyte levels were comparable to baseline, followed by a gradual decrease during radiotherapy delivery. Radiation-induced lymphopenia was generally mild overall, and HFRT resulted in less severe lymphopenia than CFRT. Compared with the CFRT group, the HFRT group had a significantly higher mean nadir PLC (1.26 ± 0.42 × 10⁹/L vs 1.05 ± 0.32 × 10⁹/L, P < 0.001) and a significantly lower grade ≥2 lymphopenia rate (6.5% vs 24.5%, P = 0.001). Despite the milder acute suppression with HFRT, PLCs experienced a prolonged reduction period in both cohorts, recovering to baseline levels at 3 years post-radiotherapy in the HFRT group and at 4 years in the CFRT group. The authors concluded that these findings provide additional evidence supporting the clinical use of HFRT while highlighting the need for strategies to minimize radiation-induced lymphopenia and promote lymphocyte recovery.

    Key Takeaways

    • Hypofractionated radiotherapy resulted in a significantly lower rate of grade ≥2 lymphopenia (6.5% vs 24.5%, P = 0.001) and a significantly higher mean nadir peripheral lymphocyte count (1.26 ± 0.42 × 10⁹/L vs 1.05 ± 0.32 × 10⁹/L, P < 0.001) compared with conventional fractionated radiotherapy.
    • Peripheral lymphocyte counts experienced a prolonged reduction period across both arms, returning to baseline levels at 3 years following hypofractionated radiotherapy and at 4 years following conventional fractionated radiotherapy.
    Read the original sourceTherapeutic advances in medical oncology